Complementary and alternative therapies for Crohn’s disease, like acupuncture and meditation, are useful approaches to managing symptoms in combination with a treatment plan.

The FDA approval of Selarsdi 130 mg/26 ml in a single-dose vial for intravenous infusion expands the label to include ...

Breastfeeding, child nutrition and exposure to secondhand tobacco smoke at an early age may play a role in the onset of ...

After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

It was how it would affect him socially.Being in his early 20s at the time, Kefford was focused on socialising and dating, ...

There is a strong connection between inflammatory bowel disease (IBD) and spondyloarthritis—a condition that causes pain and ...

Eli Lilly and Johnson & Johnson both touted data Monday for their IL-23 inhibitors in Crohn’s disease, with Lilly also ...

Crohn’s disease is a type of inflammatory bowel disease (IBD) that involves periods of remission and flares. Symptoms can ...

Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative ...

Johnson & Johnson's Tremfya shows promising results in Phase 3 GRAVITI study for Crohn's disease, achieving significant clinical remission and endoscopic response at 48 weeks.

Eli Lilly (LLY) announced results from two, multi-year, Phase 3 studies that showed patients treated with mirikizumab sustained stable, ...